Rafferty Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Rafferty Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$830K	Sell	221,377 -18,447	-8%	-$70.4K	﹤0.01%	821
2026 Q1	$1.13M	Sell	239,824 -33,760	-12%	-$171K	﹤0.01%	734
2025 Q4	$1.17M	Buy	+273,584	New	+$1.04M	﹤0.01%	766
2022 Q1	–	Sell	-152,369	Closed	-$660K	–	1237
2021 Q4	$660K	Sell	152,369 -5,932	-4%	-$34.8K	﹤0.01%	1010
2021 Q3	$806K	Sell	158,301 -36,985	-19%	-$198K	0.01%	922
2021 Q2	$1.24M	Buy	195,286 +32,629	+20%	+$254K	0.01%	811
2021 Q1	$1.26M	Buy	162,657 +145,950	+874%	+$1.16M	0.01%	718
2020 Q4	$109K	Sell	16,707 -32,101	-66%	-$229K	﹤0.01%	1002
2020 Q3	$325K	Buy	48,808 +26,638	+120%	+$198K	﹤0.01%	789
2020 Q2	$185K	Buy	+22,170	New	+$206K	﹤0.01%	932
2019 Q4	–	Sell	-65,510	Closed	-$483K	–	877
2019 Q3	$483K	Sell	65,510 -7,131	-10%	-$70.3K	0.01%	667
2019 Q2	$815K	Sell	72,641 -17,854	-20%	-$187K	0.01%	600
2019 Q1	$973K	Buy	+90,495	New	+$1.34M	0.02%	554

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Rafferty Asset Management's CTMX Position: Q2 2026 in Review

Rafferty Asset Management reduced its CytomX Therapeutics (CTMX) stake by 7.7% in Q2 2026, selling an estimated $70.4K and leaving 221,377 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Rafferty Asset Management first reported a position in CTMX in Q1 2019 and has held it in 13 quarters since. The position peaked at $1.26M in Q1 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Rafferty Asset Management held 221,377 shares of CytomX Therapeutics worth $830K as of Q2 2026.
Rafferty Asset Management sold 18,447 CytomX Therapeutics shares in Q2 2026, an estimated $70.4K.
CytomX Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #821 holding.
Rafferty Asset Management first reported a position in CytomX Therapeutics in Q1 2019 and has held it in 13 quarters since.
Rafferty Asset Management's CytomX Therapeutics position peaked at $1.26M in Q1 2021.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.